Cabot Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cabot in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cabot stock.
View analyst ratings for Cabot or view top-rated stocks.

Wall Street analysts have given Cabot a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cabot wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cabot is scheduled to release its next quarterly earnings announcement on Monday, November 22nd 2021.
View our earnings forecast for Cabot.

Cabot Co. (NYSE:CBT) released its quarterly earnings data on Sunday, August, 8th. The specialty chemicals company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.17. The specialty chemicals company earned $917 million during the quarter, compared to analyst estimates of $804.70 million. Cabot had a negative net margin of 1.61% and a positive trailing twelve-month return on equity of 27.56%. Cabot's revenue for the quarter was up 77.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.07) earnings per share.
View Cabot's earnings history.

Cabot's stock was trading at $29.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CBT stock has increased by 66.8% and is now trading at $49.88.
View which stocks have been most impacted by COVID-19.

Cabot declared a quarterly dividend on Friday, July 9th. Stockholders of record on Friday, August 27th will be given a dividend of $0.35 per share on Friday, September 10th. This represents a $1.40 annualized dividend and a yield of 2.81%. The ex-dividend date is Thursday, August 26th.
View Cabot's dividend history.

Cabot pays an annual dividend of $1.40 per share and currently has a dividend yield of 2.78%. The dividend payout ratio of Cabot is 67.31%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Cabot will have a dividend payout ratio of 25.27% next year. This indicates that Cabot will be able to sustain or increase its dividend.
View Cabot's dividend history.

Cabot issued an update on its FY 2021 earnings guidance on Monday, September, 6th. The company provided earnings per share (EPS) guidance of $4.850-$5.050 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.920. The company issued revenue guidance of -.

8 brokers have issued 12-month price targets for Cabot's shares. Their forecasts range from $45.00 to $143.00. On average, they anticipate Cabot's stock price to reach $74.38 in the next year. This suggests a possible upside of 49.1% from the stock's current price.
View analysts' price targets for Cabot or view top-rated stocks among Wall Street analysts.

40 employees have rated Cabot CEO Sean Keohane on Glassdoor.com. Sean Keohane has an approval rating of 96% among Cabot's employees. This puts Sean Keohane in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Cabot include LyondellBasell Industries (LYB), Westlake Chemical (WLK), Kronos Worldwide (KRO), Hawkins (HWKN), Koppers (KOP), Tredegar (TG) and Trecora Resources (TREC).
View all of CBT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabot investors own include Pfizer (PFE), Broadcom (AVGO), Energy Transfer (ET), AT&T (T), Gilead Sciences (GILD), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and The Coca-Cola (KO).

Cabot trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBT."

Cabot's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (10.94%), Vanguard Group Inc. (10.17%), Fuller & Thaler Asset Management Inc. (5.36%), LSV Asset Management (4.57%), Victory Capital Management Inc. (3.45%) and State Street Corp (3.19%). Company insiders that own Cabot stock include Hobart Kalkstein and Karen A Kalita.
View institutional ownership trends for Cabot.

CBT stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Victory Capital Management Inc., AQR Capital Management LLC, Millennium Management LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, State Board of Administration of Florida Retirement System, and Russell Investments Group Ltd..
View insider buying and selling activity for Cabot or view top insider-selling stocks.

CBT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Citigroup Inc., Macquarie Group Ltd., Vanguard Group Inc., Northern Trust Corp, Geode Capital Management LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Cabot or or view top insider-buying stocks.

Shares of CBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CBT stock can currently be purchased for approximately $49.88.

Cabot has a market capitalization of $2.83 billion and generates $2.61 billion in revenue each year. The specialty chemicals company earns $-238,000,000.00 in net income (profit) each year or $2.08 on an earnings per share basis.

Cabot employs 4,500 workers across the globe.

The official website for Cabot is www.cabot-corp.com.

Cabot is headquartered at TWO SEAPORT LANE SUITE 1300, BOSTON MA, 02210.

Cabot's mailing address is TWO SEAPORT LANE SUITE 1300, BOSTON MA, 02210. The specialty chemicals company can be reached via phone at (617) 345-0100 or via email at [email protected]